Application of glutathione as anti-oxidative and anti-aging drugs

Current Drug Metabolism

Volumn 16, Issue 7, 2015, Pages 560-571

  Homma, Takujiro ^a   Fujii, Junichi ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Cell death; Cysteine; Glutathione; N acetylcysteine; Oxidative stress

Indexed keywords

ANTIOXIDANT; CYSTEINE; EXCITATORY AMINO ACID TRANSPORTER 3; GLUTATHIONE; LIPOXYGENASE;

AGING; AMINO ACID SYNTHESIS; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CATALYSIS; CELL DEATH; CHEMICAL MODIFICATION; DEGENERATIVE DISEASE; ENDOPLASMIC RETICULUM; EXTRACELLULAR FLUID; GLUTATHIONE METABOLISM; HUMAN; LIPID PEROXIDATION; LYSOSOME; MINERAL SUPPLEMENTATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; TRANSSULFURATION; ANIMAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; OXIDATION REDUCTION REACTION; PHYSIOLOGY;

AGING; ANIMALS; ANTIOXIDANTS; CELL DEATH; GLUTATHIONE; HUMANS; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 84958116555     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200216666151015114515     Document Type: Article

References (179)

1. Meyer, Y.; Buchanan, B. B.; Vignols, F.; Reichheld, J.-P. Thioredoxins and glutaredoxins: unifying elements in redox biology. Annu. Rev. Genet., 2009, 43, 335-367.
2. Franco, R.; Cidlowski, J. A. Apoptosis and glutathione: beyond an antioxidant. Cell Death Differ., 2009, 16, 1303-1314.
3. Circu, M. L.; Aw, T. Y. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic. Biol. Med., 2010, 48, 749-762.
4. Sian, J.; Dexter, D. T.; Lees, A. J.; Daniel, S.; Agid, Y.; Javoy-Agid, F.; Jenner, P.; Marsden, C. D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol., 1994, 36, 348-355.
5. Sian, J.; Dexter, D. T.; Lees, A. J.; Daniel, S.; Jenner, P.; Marsden, C. D. Glutathione-related enzymes in brain in Parkinson's disease. Ann. Neurol., 1994, 36, 356-361.
6. Smeyne, M.; Smeyne, R. J. Glutathione metabolism and Parkinson's disease. Free Radic. Biol. Med., 2013, 62, 13-25.
7. Dixon, S. J.; Lemberg, K. M.; Lamprecht, M. R.; Skouta, R.; Zaitsev, E. M.; Gleason, C. E.; Patel, D. N.; Bauer, A. J.; Cantley, A. M.; Yang, W. S.; Morrison, B.; Stockwell, B. R. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell, 2012, 149, 1060-1072.
8. Yang, W. S.; Sriramaratnam, R.; Welsch, M. E.; Shimada, K.; Skouta, R.; Viswanathan, V. S.; Cheah, J. H.; Clemons, P. a.; Shamji, A. F.; Clish, C. B.; Brown, L. M.; Girotti, A. W.; Cornish, V. W.; Schreiber, S. L.; Stockwell, B. R. Regulation of ferroptotic cancer cell death by GPX4. Cell, 2014, 156, 317-331.
9. Berg, D.; Gerlach, M.; Youdim, M. B. H.; Double, K. L.; Zecca, L.; Riederer, P.; Becker, G. Brain iron pathways and their relevance to Parkinson's disease. J. Neurochem., 2001, 79, 225-236.
10. Zecca, L.; Youdim, M. B. H.; Riederer, P.; Connor, J. R.; Crichton, R. R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci., 2004, 5, 863-873.
11. Ward, P. R. J.; Zucca, F. a; Duyn, J. H.; Crichton, P. R. R.; Zecca, L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol., 2014, 13, 1045-1060.
12. Cacciatore, I.; Cornacchia, C.; Pinnen, F.; Mollica, A.; Di Stefano, A. Prodrug approach for increasing cellular glutathione levels. Molecules, 2010, 15, 1242-1264.
13. Bavarsad Shahripour, R.; Harrigan, M. R.; Alexandrov, A. V Nacetylcysteine (NAC) in neurological disorders: Mechanisms of action and therapeutic opportunities. Brain Behav., 2014, 4, 108-122.
14. Paul, B. D.; Sbodio, J. I.; Xu, R.; Vandiver, M. S.; Cha, J. Y.; Snowman, A. M.; Snyder, S. H. Cystathionine γ-lyase deficiency mediates neurodegeneration in Huntington's disease. Nature, 2014, 509, 96-100.
15. Ballatori, N.; Krance, S. M.; Marchan, R.; Hammond, C. L. Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology. Mol. Aspects Med., 2009, 30, 13-28.
16. Griffith, O. W. Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J. Biol. Chem., 1982, 257, 13704-13712.
17. Sabirov, R. Z.; Kurbannazarova, R. S.; Melanova, N. R.; Okada, Y. Volume-Sensitive Anion Channels Mediate Osmosensitive Glutathione Release from Rat Thymocytes. PLoS One, 2013, 8.
18. Fujii, J.; Ito, J. I.; Zhang, X.; Kurahashi, T. Unveiling the roles of the glutathione redox system in vivo by analyzing genetically modified mice. J. Clin. Biochem. Nutr., 2011, 49, 70-78.
19. Harvey, C. J.; Thimmulappa, R. K.; Singh, a.; Blake, D. J.; Ling, G.; Wakabayashi, N.; Fujii, J.; Myers, A.; Biswal, S. Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. Free Radic. Biol. Med., 2009, 46, 443-453.
20. Sasaki, H.; Sato, H.; Kuriyama-Matsumura, K.; Sato, K.; Maebara, K.; Wang, H.; Tamba, M.; Itoh, K.; Yamamoto, M.; Bannai, S. Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression. J. Biol. Chem., 2002, 277, 44765-44771.
21. Conrad, M.; Sato, H. The oxidative stress-inducible cystine/glutamate antiporter, system xc-: Cystine supplier and beyond. Amino Acids, 2012, 42, 231-246.
22. Chairoungdua, A.; Segawa, H.; Kim, J. Y.; Miyamoto, K.; Haga, H.; Fukui, Y.; Mizoguchi, K.; Ito, H.; Takeda, E.; Endou, H.; Kanai, Y. Identification of an amino acid transporter associated with the cystinuria-related type II membrane glycoprotein. J. Biol. Chem., 1999, 274, 28845-28848.
23. Van Winkle, L. J.; Campione, A. L.; Gorman, J. M. Na+-independent transport of basic and zwitterionic amino acids in mouse blastocysts by a shared system and by processes which distinguish between these substrates. J. Biol. Chem., 1988, 263, 3150-3163.
24. Rajan, D. P.; Kekuda, R.; Huang, W.; Wang, H.; Devoe, L. D.; Leibach, F. H.; Prasad, P. D.; Ganapathy, V. Cloning and expression of a b(0,+)-like amino acid transporter functioning as a heterodimer with 4F2hc instead of rBAT. A new candidate gene for cystinuria. J. Biol. Chem., 1999, 274, 29005-29010.
25. Pfeiffer, R.; Loffing, J.; Rossier, G.; Bauch, C.; Meier, C.; Eggermann, T.; Loffing-Cueni, D.; Kühn, L. C.; Verrey, F. Luminal heterodimeric amino acid transporter defective in cystinuria. Mol. Biol. Cell, 1999, 10, 4135-4147.
26. Bannai, S. Exchange of cystine and glutamate across plasma membrane of human fibroblasts. J. Biol. Chem., 1986, 261, 2256-2263.
27. Sato, H.; Tamba, M.; Ishii, T.; Bannai, S. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J. Biol. Chem., 1999, 274, 11455-11458.
28. Bannai, S.; Ishii, T. Formation of sulfhydryl groups in the culture medium by human diploid fibroblasts. J. Cell. Physiol., 1980, 104, 215-223.
29. Watanabe, H.; Bannai, S. Induction of cystine transport activity in mouse peritoneal macrophages. J. Exp. Med., 1987, 165, 628-640.
30. Sakakura, Y.; Sato, H.; Shiiya, A.; Tamba, M.; Sagara, J.; Matsuda, M.; Okamura, N.; Makino, N.; Bannai, S. Expression and function of cystine/glutamate transporter in neutrophils. J. Leukoc. Biol., 2007, 81, 974-982.
31. Bannai, S.; Sato, H.; Ishii, T.; Sugita, Y. Induction of cystine transport activity in human fibroblasts by oxygen. J. Biol. Chem., 1989, 264, 18480-18484.
32. Sato, H.; Fujiwara, K.; Sagara, J.; Bannai, S. Induction of cystine transport activity in mouse peritoneal macrophages by bacterial lipopolysaccharide. Biochem. J., 1995, 310 (Pt 2), 547-551.
33. Lewerenz, J.; Maher, P. Basal levels of eIF2alpha phosphorylation determine cellular antioxidant status by regulating ATF4 and xCT expression. J. Biol. Chem., 2009, 284, 1106-1115.
34. Tsujita, T.; Peirce, V.; Baird, L.; Matsuyama, Y.; Takaku, M.; Walsh, S. V.; Griffin, J. L.; Uruno, a.; Yamamoto, M.; Hayes, J. D. Transcription Factor Nrf1 Negatively Regulates the Cystine/Glutamate Transporter and Lipid-Metabolizing Enzymes. Mol. Cell. Biol., 2014, 34, 3800-3816.
35. Miller, V. M.; Lawrence, D. A.; Mondal, T. K.; Seegal, R. F. Reduced glutathione is highly expressed in white matter and neurons in the unperturbed mouse brain-Implications for oxidative stress associated with neurodegeneration. Brain Res., 2009, 1276, 22-30.
36. Burdo, J.; Dargusch, R.; Schubert, D. Distribution of the cystine/glutamate antiporter system xc-in the brain, kidney, and duodenum. J. Histochem. Cytochem., 2006, 54, 549-557.
37. Jackman, N. A.; Uliasz, T. F.; Hewett, J. A.; Hewett, S. J. Regulation of system xc-Activity and expression in astrocytes by interleukin-1: implications for hypoxic neuronal injury. Glia, 2010, 58, 1806-1815.
38. Seib, T. M.; Patel, S. A.; Bridges, R. J. Regulation of the system x(C)-cystine/glutamate exchanger by intracellular glutathione levels in rat astrocyte primary cultures. Glia, 2011, 59, 1387-1401.
39. Pampliega, O.; Domercq, M.; Soria, F. N.; Villoslada, P.; Rodríguez-Antigüedad, A.; Matute, C. Increased expression of cystine/glutamate antiporter in multiple sclerosis. J. Neuroinflammation, 2011, 8, 63.
40. Piani, D.; Fontana, A. Involvement of the cystine transport system xc-in the macrophage-induced glutamate-dependent cytotoxicity to neurons. J. Immunol., 1994, 152, 3578-3585.
41. Qin, S.; Colin, C.; Hinners, I.; Gervais, A.; Cheret, C.; Mallat, M. System Xc-And apolipoprotein E expressed by microglia have opposite effects on the neurotoxicity of amyloid-beta peptide 1-40. J. Neurosci., 2006, 26, 3345-3356.
42. Mesci, P.; Zaïdi, S.; Lobsiger, C. S.; Millecamps, S.; Escartin, C.; Seilhean, D.; Sato, H.; Mallat, M.; Boillée, S. System xc-is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice. Brain, 2014, 7, 1-16.
43. De Bundel, D.; Schallier, A.; Loyens, E.; Fernando, R.; Miyashita, H.; Van Liefferinge, J.; Vermoesen, K.; Bannai, S.; Sato, H.; Michotte, Y.; Smolders, I.; Massie, A. Loss of system xc-does not induce oxidative stress but decreases extracellular glutamate in hippocampus and influences spatial working memory and limbic seizure susceptibility. J. Neurosci., 2011, 31, 5792-5803.
44. Sato, H.; Shiiya, A.; Kimata, M.; Maebara, K.; Tamba, M.; Sakakura, Y.; Makino, N.; Sugiyama, F.; Yagami, K. I.; Moriguchi, T.; Takahashi, S.; Bannai, S. Redox imbalance in cystine/glutamate transporter-deficient mice. J. Biol. Chem., 2005, 280, 37423-37429.
45. Shibasaki, T.; Iuchi, Y.; Okada, F.; Kuwata, K.; Yamanobe, T.; Bannai, S.; Tomita, Y.; Sato, H.; Fujii, J. Aggravation of ischemiareperfusion-triggered acute renal failure in xCT-deficient mice. Arch. Biochem. Biophys., 2009, 490, 63-69.
46. Kobayashi, S.; Kuwata, K.; Sugimoto, T.; Igarashi, K.; Osaki, M.; Okada, F.; Fujii, J.; Bannai, S.; Sato, H. Enhanced expression of cystine/glutamate transporter in the lung caused by the oxidativestress-inducing agent paraquat. Free Radic. Biol. Med., 2012, 53, 2197-2203.
47. Kobayashi, S.; Sato, M.; Kasakoshi, T.; Tsutsui, T.; Sugimoto, M.; Osaki, M.; Okada, F.; Igarashi, K.; Hiratake, J.; Homma, T.; Conrad, M.; Fujii, J.; Soga, T.; Bannai, S.; Sato, H. Cystathionine is a Novel Substrate of Cystine/glutamate Transporter: Implications for Immune Function. J. Biol. Chem., 2015, 290, 8778-88.
48. Kanai, Y.; Hediger, M. A. Primary structure and functional characterization of a high-Affinity glutamate transporter. Nature, 1992, 360, 467-471.
49. Zerangue, N.; Kavanaugh, M. P. Interaction of L-cysteine with a human excitatory amino acid transporter. J. Physiol., 1996, 493 (Pt 2), 419-423.
50. Lee, S. A.; Choi, J. G.; Zuo, Z. Volatile anesthetics attenuate oxidative stress-reduced activity of glutamate transporter type 3. Anesth. Analg., 2009, 109, 1506-1510.
51. Aoyama, K.; Suh, S. W.; Hamby, A. M.; Liu, J.; Chan, W. Y.; Chen, Y.; Swanson, R. A. Neuronal glutathione deficiency and agedependent neurodegeneration in the EAAC1 deficient mouse. Nat. Neurosci., 2006, 9, 119-126.
52. Sagara, J. I.; Miura, K.; Bannai, S. Maintenance of neuronal glutathione by glial cells. J. Neurochem., 1993, 61, 1672-1676.
53. Kranich, O.; Hamprecht, B.; Dringen, R. Different preferences in the utilization of amino acids for glutathione synthesis in cultured neurons and astroglial cells derived from rat brain. Neurosci. Lett., 1996, 219, 211-214.
54. Won, S. J.; Yoo, B. H.; Brennan, A. M.; Shin, B. S.; Kauppinen, T. M.; Berman, A. E.; Swanson, R. A.; Suh, S. W. EAAC1 gene deletion alters zinc homeostasis and exacerbates neuronal injury after transient cerebral ischemia. J. Neurosci., 2010, 30, 15409-15418.
55. Jang, B. G.; Won, S. J.; Kim, J. H.; Choi, B. Y.; Lee, M. W.; Sohn, M.; Song, H. K.; Suh, S. W. EAAC1 gene deletion alters zinc homeostasis and enhances cortical neuronal injury after transient cerebral ischemia in mice. J. Trace Elem. Med. Biol., 2012, 26, 85-88.
56. Ruggiero, A. M.; Liu, Y.; Vidensky, S.; Maier, S.; Jung, E.; Farhan, H.; Robinson, M. B.; Sitte, H. H.; Rothstein, J. D. The endoplasmic reticulum exit of glutamate transporter is regulated by the inducible mammalian Yip6b/GTRAP3-18 protein. J. Biol. Chem., 2008, 283, 6175-6183.
57. Aoyama, K.; Wang, F.; Matsumura, N.; Kiyonari, H.; Shioi, G.; Tanaka, K.; Kinoshita, C.; Kikuchi-Utsumi, K.; Watabe, M.; Nakaki, T. Increased neuronal glutathione and neuroprotection in GTRAP3-18-deficient mice. Neurobiol. Dis., 2012, 45, 973-982.
58. Lu, S. C. Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J., 1999, 13, 1169-83.
59. Mani, S.; Cao, W.; Wu, L.; Wang, R. Hydrogen sulfide and the liver. Nitric Oxide-Biol. Chem., 2014.
60. Kabil, O.; Vitvitsky, V.; Xie, P.; Banerjee, R. The quantitative significance of the transsulfuration enzymes for H2S production in murine tissues. Antioxid. Redox Signal., 2011, 15, 363-372.
61. Medici, V.; Peerson, J. M.; Stabler, S. P.; French, S. W.; Gregory, J. F.; Virata, M. C.; Albanese, A.; Bowlus, C. L.; Devaraj, S.; Panacek, E. a.; Rahim, N.; Richards, J. R.; Rossaro, L.; Halsted, C. H. Impaired homocysteine transsulfuration is an indicator of alcoholic liver disease. J. Hepatol., 2010, 53, 551-557.
62. Kang, K.; Zhao, M.; Jiang, H.; Tan, G.; Pan, S.; Sun, X. Role of hydrogen sulfide in hepatic ischemia-reperfusion-induced injury in rats. Liver Transplant., 2009, 15, 1306-1314.
63. Jung, K. J.; Jang, H. S.; Kim, J. I.; Han, S. J.; Park, J. W.; Park, K. M. Involvement of hydrogen sulfide and homocysteine transsulfuration pathway in the progression of kidney fibrosis after ureteral obstruction. Biochim. Biophys. Acta-Mol. Basis Dis., 2013, 1832, 1989-1997.
64. Hine, C.; Harputlugil, E.; Zhang, Y.; Ruckenstuhl, C.; Lee, B.C.; Brace, L.; Longchamp, A.; Treviño-Villarreal, J.H.; Mejia, P.; Ozaki, C.K.; Wang, R.; Gladyshev, V.N.; Madeo, F.; Mair, W.B.; Mitchell J.Hine, C.; Harputlugil, E.; Zhang, Y.; Ruckenstuhl, C.; Lee, B.C.; Brace, L.; Longchamp, A.; Treviño-, M. J. Endogenous Hydrogen Sulfide Production Is Essential for Dietary Restriction Benefits. Cell, 2014, 160, 132-44.
65. Maher, P. The effects of stress and aging on glutathione metabolism. Ageing Res. Rev., 2005, 4, 288-314.
66. Christon, R.; Haloui, R. B.; Durand, G. Dietary polyunsaturated fatty acids and aging modulate glutathione-related antioxidants in rat liver. J. Nutr., 1995, 125, 3062-3070.
67. Palomero, J.; Galán, A. I.; Muoz, M. E.; Tuón, M. J.; González-Gallego, J.; Jiménez, R. Effects of aging on the susceptibility to the toxic effects of cyclosporin A in rats. Changes in liver glutathione and antioxidant enzymes. Free Radic. Biol. Med., 2001, 30, 836-845.
68. Liu, R.-M.; Dickinson, D. A. Decreased synthetic capacity underlies the age-Associated decline in glutathione content in Fisher 344 rats. Antioxid. Redox Signal., 2003, 5, 529-536.
69. Mosoni, L.; Breuillé, D.; Buffiére, C.; Obled, C.; Mirand, P. P. Age-related changes in glutathione availability and skeletal muscle carbonyl content in healthy rats. Exp. Gerontol., 2004, 39, 203-210.
70. Rebrin, I.; Kamzalov, S.; Sohal, R. S. Effects of age and caloric restriction on glutathione redox state in mice. Free Radic. Biol. Med., 2003, 35, 626-635.
71. Nakata, K.; Kawase, M.; Ogino, S.; Kinoshita, C.; Murata, H.; Sakaue, T.; Ogata, K.; Ohmori, S. Effects of age on levels of cysteine, glutathione and related enzyme activities in livers of mice and rats and an attempt to replenish hepatic glutathione level of mouse with cysteine derivatives. Mech. Ageing Dev., 1996, 90, 195-207.
72. Barja de Quiroga, G.; Pérez-Campo, R.; López Torres, M. Antioxidant defences and peroxidation in liver and brain of aged rats. Biochem. J., 1990, 272, 247-250.
73. Jiang P, Sheng Y, J. L. The age-related change of glutathione antioxidant system in mice liver. Toxicol. Mech. Methods, 2013, 23, 396-401.
74. Chen, T. S.; Richie, J. P.; Lang, C. A. The effect of aging on glutathione and cysteine levels in different regions of the mouse brain. Proc. Soc. Exp. Biol. Med., 1989, 190, 399-402.
75. Sasaki, T.; Senda, M.; Kim, S.; Kojima, S.; Kubodera, a Agerelated changes of glutathione content, glucose transport and metabolism, and mitochondrial electron transfer function in mouse brain. Nucl. Med. Biol., 2001, 28, 25-31.
76. Wang, H.; Liu, H.; Liu, R. M. Gender difference in glutathione metabolism during aging in mice. Exp. Gerontol., 2003, 38, 507-517.
77. Liu, R. Down-regulation of gamma-glutamylcysteine synthetase regulatory subunit gene expression in rat brain tissue during aging. J. Neurosci. Res., 2002, 68, 344-351.
78. Zhu, Y.; Carvey, P. M.; Ling, Z. Age-related changes in glutathione and glutathione-related enzymes in rat brain. Brain Res., 2006, 1090, 35-44.
79. Liu, R.; Choi, J. Age-Associated decline in gammaglutamylcysteine synthetase gene expression in rats. Free Radic. Biol. Med., 2000, 28, 566-574.
80. Mizuno, Y.; Ohta, S.; Tanaka, M.; Takamiya, S.; Suzuki, K.; Sato, T.; Oya, H.; Ozawa, T.; Kagawa, Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun., 1989, 163, 1450-1455.
81. Di Monte, D. A.; Chan, P.; Sandy, M. S. Glutathione in Parkinson's disease: a link between oxidative stress and mitochondrial damage? Ann. Neurol., 1992, 32 Suppl, S111-S115.
82. Riederer, P.; Sofic, E.; Rausch, W. D.; Schmidt, B.; Reynolds, G. P.; Jellinger, K.; Youdim, M. B. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem., 1989, 52, 515-520.
83. Perry, T. L.; Godin, D. V.; Hansen, S. Parkinson's disease: A disorder due to nigral glutathione deficiency? Neurosci. Lett., 1982, 33, 305-310.
84. Sofic, E.; Lange, K. W.; Jellinger, K.; Riederer, P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett., 1992, 142, 128-130.
85. Pearce, R. K. B.; Owen, A.; Daniel, S.; Jenner, P.; Marsden, C. D. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural. Transm., 1997, 104, 661-677.
86. Ilic, T. V.; Jovanovic, M.; Jovicic, A.; Tomovic, M. Oxidative stress indicators are elevated in de novo Parkinson's disease patients. Funct. Neurol., 1999, 14, 141-147.
87. Pileblad, E.; Magnusson, T.; Fornstedt, B. Reduction of brain glutathione by L-buthionine sulfoximine potentiates the dopaminedepleting action of 6-hydroxydopamine in rat striatum. J. Neurochem., 1989, 52, 978-980.
88. Chinta, S. J.; Rajagopalan, S.; Butterfield, D. A.; Andersen, J. K. In vitro and in vivo neuroprotection by γ-glutamylcysteine ethyl ester against MPTP: Relevance to the role of glutathione in Parkinson's disease. Neurosci. Lett., 2006, 402, 137-141.
89. Dalton, T. P.; Dieter, M. Z.; Yang, Y.; Shertzer, H. G.; Nebert, D. W. Knockout of the mouse glutamate cysteine ligase catalytic subunit (Gclc) gene: embryonic lethal when homozygous, and proposed model for moderate glutathione deficiency when heterozygous. Biochem. Biophys. Res. Commun., 2000, 279, 324-329.
90. Shi, Z. Z.; Osei-Frimpong, J.; Kala, G.; Kala, S. V; Barrios, R. J.; Habib, G. M.; Lukin, D. J.; Danney, C. M.; Matzuk, M. M.; Lieberman, M. W. Glutathione synthesis is essential for mouse development but not for cell growth in culture. Proc. Natl. Acad. Sci. U. S. A., 2000, 97, 5101-5106.
91. Diaz-Hernandez, J. I.; Almeida, A.; Delgado-Esteban, M.; Fernandez, E.; Bolaños, J. P. Knockdown of glutamate-cysteine by ligase by small hairpin RNA reveals that both catalytic and modulatory subunits are essential for the survival of primary neurons. J. Biol. Chem., 2005, 280, 38992-39001.
92. Steinherz, R.; Mårtensson, J.; Wellner, D.; Meister, A. Transport into brain of buthionine sulfoximine, an inhibitor of glutathione synthesis, is facilitated by esterification and administration of dimethylsulfoxide. Brain Res., 1990, 518, 115-119.
93. Merad-Boudia, M.; Nicole, A.; Santiard-Baron, D.; Saillé, C.; Ceballos-Picot, I. Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: Relevance to Parkinson's disease. Biochem. Pharmacol., 1998, 56, 645-655.
94. Froissard, P.; Monrocq, H.; Duval, D. Role of glutathione metabolism in the glutamate-induced programmed cell death of neuronal-like PC12 cells. Eur. J. Pharmacol., 1997, 326, 93-99.
95. Murphy, T. H.; Miyamoto, M.; Sastre, A; Schnaar, R. L.; Coyle, J. T. Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron, 1989, 2, 1547-1558.
96. Jha, N.; Jurma, O.; Lalli, G.; Liu, Y.; Pettus, E. H.; Greenamyre, J. T.; Liu, R. M.; Forman, H. J.; Andersen, J. K. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. J. Biol. Chem., 2000, 275, 26096-26101.
97. Ghibelli, L.; Coppola, S.; Fanelli, C.; Rotilio, G.; Civitareale, P.; Scovassi, a I.; Ciriolo, M. R. Glutathione depletion causes cytochrome c release even in the absence of cell commitment to apoptosis. FASEB J., 1999, 13, 2031-2036.
98. Wullner, U.; Seyfried, J.; Groscurth, P.; Beinroth, S.; Winter, S.; Gleichmann, M.; Heneka, M.; Loschmann, P.; Schulz, J. B.; Weller, M.; Klockgether, T. Glutathione depletion and neuronal cell death: the role of reactive oxygen intermediates and mitochondrial function. Brain Res., 1999, 826, 53-62.
99. Seyfried, J.; Soldner, F.; Schulz, J. B.; Klockgether, T.; Kovar, K. A.; Wüllner, U. Differential effects of L-buthionine sulfoximine and ethacrynic acid on glutathione levels and mitochondrial function in PC12 cells. Neurosci. Lett., 1999, 264, 1-4.
100. Dasgupta, A.; Zheng, J.; Bizzozero, O. A. Protein carbonylation and aggregation precede neuronal apoptosis induced by partial glutathione depletion. ASN Neuro., 2012, 4, 161-174.
101. Friesen, C.; Kiess, Y.; Debatin, K. A critical role of glutathione in determining apoptosis sensitivity and resistance in leukemia cells. Cell Death Differ., 2004, 11 Suppl 1, S73-S85.
102. Armstrong, J. S.; Steinauer, K. K.; Hornung, B.; Irish, J. M.; Lecane, P.; Birrell, G. W.; Peehl, D. M.; Knox, S. J. Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Cell Death Differ., 2002, 9, 252-263.
103. Muyderman, H.; Wadey, A. L.; Nilsson, M.; Sims, N. R. Mitochondrial glutathione protects against cell death induced by oxidative and nitrative stress in astrocytes. J. Neurochem., 2007, 102, 1369-1382.
104. Cho, Y.; Bannai, S. Uptake of glutamate and cysteine in C-6 glioma cells and in cultured astrocytes. J. Neurochem., 1990, 55, 2091-2097.
105. Pereira, C. M. F.; Oliveira, C. R. Glutamate toxicity on a PC12 cell line involves glutathione (GSH) depletion and oxidative stress. Free Radic. Biol. Med., 1997, 23, 637-647.
106. Sagara, Y.; Dargusch, R.; Chambers, D.; Davis, J.; Schubert, D.; Maher, P. Cellular mechanisms of resistance to chronic oxidative stress. Free Radic. Biol. Med., 1998, 24, 1375-1389.
107. Sen, C. K.; Khanna, S.; Roy, S.; Packer, L. Molecular basis of vitamin E action. Tocotrienol potently inhibits glutamate-induced pp(60c-Src) kinase activation and death of HT4 neuronal cells. J. Biol. Chem., 2000, 275, 13049-13055.
108. Tirosh, O.; Sen, C. K.; Roy, S.; Packer, L. Cellular and mitochondrial changes in glutamate-induced HT4 neuronal cell death. Neuroscience, 2000, 97, 531-541.
109. Schubert, D.; Kimura, H.; Maher, P. Growth factors and vitamin E modify neuronal glutamate toxicity. Proc. Natl. Acad. Sci. U. S. A., 1992, 89, 8264-8267.
110. Mayer, M.; Noble, M. N-Acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc. Natl. Acad. Sci. U. S. A., 1994, 91, 7496-7500.
111. Li, Y.; Maher, P.; Schubert, D. A role of 12-lipoxygenase in nerve cell death caused by glutathione depletion. J. Cell Biol., 1997, 139, 1317-1324.
112. Van Leyen, K.; Kim, H. Y.; Lee, S. R.; Jin, G.; Arai, K.; Lo, E. H. Baicalein and 12/15-lipoxygenase in the ischemic brain. Stroke, 2006, 37, 3014-3018.
113. Hagmann, W.; Kagawa, D.; Renaud, C.; Honn, K. V. Activity and protein distribution of 12-lipoxygenase in HEL cells: induction of membrane-Association by phorbol ester TPA, modulation of activity by glutathione and 13-HPODE, and Ca(2+)-dependent translocation to membranes. Prostaglandins, 1993, 46, 471-477.
114. Shornick, L. P.; Holtzman, M. J. A cryptic, microsomal-type arachidonate 12-lipoxygenase is tonically inactivated by oxidationreduction conditions in cultured epithelial cells. J. Biol. Chem., 1993, 268, 371-376.
115. Sautebin, L.; Spagnuolo, C.; Galli, C.; Galli, G. A mass fragmentographic procedure for the simultaneous determination of HETE and PGF2alpha in the central nervous system. Prostaglandins, 1978, 16, 985-988.
116. Shimizu, T.; Takusagawa, Y.; Izumi, T.; Ohishi, N.; Seyama, Y. Enzymic synthesis of leukotriene B4 in guinea pig brain. J. Neurochem., 1987, 48, 1541-1546.
117. Le Foll, I.; Duval, D. P. Programmed cell death induced by glutathione depletion in PC 12 cells is blocked by inhibitors of 12 lipoxygenase, but does not appear to be mediated through the formation of 12 HETE derivatives. Free Radic. Biol. Med., 2001, 30, 793-802.
118. Okuda, S.; Saito, H.; Katsuki, H. Arachidonic acid: toxic and trophic effects on cultured hippocampal neurons. Neuroscience, 1994, 63, 691-699.
119. Wang, H.; Li, J.; Follett, P. L.; Zhang, Y.; Cotanche, D. A; Jensen, F. E.; Volpe, J. J.; Rosenberg, P. A. 12-Lipoxygenase plays a key role in cell death caused by glutathione depletion and arachidonic acid in rat oligodendrocytes. Eur. J. Neurosci., 2004, 20, 2049-2058.
120. Park, H.; Khanna, S.; Rink, C.; Gnyawali, S.; Roy, S.; Sen, C. K. Glutathione disulfide induces neural cell death via a 12-lipoxygenase pathway. Cell Death Differ., 2009, 16, 1167-1179.
121. Ivanov, I.; Heydeck, D.; Hofheinz, K.; Roffeis, J.; O'Donnell, V. B.; Kuhn, H.; Walther, M. Molecular enzymology of lipoxygenases. Arch. Biochem. Biophys., 2010, 503, 161-174.
122. Chouraqui, E.; Leon, A.; Repesse, Y.; Prigent-Tessier, A.; Bouhallab, S.; Bougle, D.; Marie, C.; Duval, D. Deferoxamine blocks death induced by glutathione depletion in PC 12 cells. Neurotoxicology, 2013, 37, 221-230.
123. Ben-Shachar, D.; Eshel, G.; Finberg, J. P.; Youdim, M. B. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamineinduced degeneration of nigrostriatal dopamine neurons. J. Neurochem., 1991, 56, 1441-1444.
124. Farinelli, S. E.; Greene, L. A. Cell cycle blockers mimosine, ciclopirox, and deferoxamine prevent the death of PC12 cells and postmitotic sympathetic neurons after removal of trophic support. J. Neurosci. 1996, 16, 1150-1162.
125. Sarco, D. P.; Becker, J.; Palmer, C.; Sheldon, R. A.; Ferriero, D. M. The neuroprotective effect of deferoxamine in the hypoxic ischemic immature mouse brain. Neurosci. Lett., 2000, 282, 113-116.
126. Kaur, D.; Andersen, J. K. Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility? Aging Cell, 2002, 1, 17-21.
127. Schenck, J. F.; Zimmerman, E. A. High-field magnetic resonance imaging of brain iron: Birth of a biomarker? NMR Biomed., 2004, 17, 433-445.
128. Wang, X.; Quinn, P. J. Vitamin E and its function in membranes. Prog. Lipid Res., 1999, 38, 309-336.
129. Boya, P.; Kroemer, G. Lysosomal membrane permeabilization in cell death. Oncogene, 2008, 27, 6434-6451.
130. Cirman, T.; Orešić, K.; Mazovec, G. D.; Turk, V.; Reed, J. C.; Myers, R. M.; Salvesen, G. S.; Turk, B. Selective Disruption of Lysosomes in HeLa Cells Triggers Apoptosis Mediated by Cleavage of Bid by Multiple Papain-like Lysosomal Cathepsins. J. Biol. Chem., 2004, 279, 3578-3587.
131. Guicciardi, M. E.; Leist, M.; Gores, G. J. Lysosomes in cell death. Oncogene, 2004, 23, 2881-2890.
132. Foghsgaard, L.; Wissing, D.; Mauch, D.; Lademann, U.; Bastholm, L.; Boes, M.; Elling, F.; Leist, M.; Jäättelä, M. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J. Cell Biol., 2001, 153, 999-1010.
133. Zhao, M.; Antunes, F.; Eaton, J. W.; Brunk, U. T. Lysosomal enzymes promote mitochondrial oxidant production, cytochrome c release and apoptosis. Eur. J. Biochem., 2003, 270, 3778-3786.
134. Chen, Q.-Y.; Shi, J.-G.; Yao, Q.-H.; Jiao, D.-M.; Wang, Y.-Y.; Hu, H.-Z.; Wu, Y.-Q.; Song, J.; Yan, J.; Wu, L.-J. Lysosomal membrane permeabilization is involved in curcumin-induced apoptosis of A549 lung carcinoma cells. Mol. Cell. Biochem., 2012, 359, 389-398.
135. Eaton, J. W.; Qian, M. Molecular bases of cellular iron toxicity. Free Radic. Biol. Med., 2002, 32, 833-840.
136. Doulias, P. T.; Christoforidis, S.; Brunk, U. T.; Galaris, D. Endosomal and lysosomal effects of desferrioxamine: Protection of HeLa cells from hydrogen peroxide-induced DNA damage and induction of cell-cycle arrest. Free Radic. Biol. Med., 2003, 35, 719-728.
137. Yu, Z.; Eaton, J. W.; Persson, H. L. The radioprotective agent, amifostine, suppresses the reactivity of intralysosomal iron. Redox Rep., 2003, 8, 347-355.
138. Kurz, T.; Gustafsson, B.; Brunk, U. T. Intralysosomal iron chelation protects against oxidative stress-induced cellular damage. FEBS J., 2006, 273, 3106-3117.
139. Persson, H. L.; Yu, Z.; Tirosh, O.; Eaton, J. W.; Brunk, U. T. Prevention of oxidant-induced cell death by lysosomotropic iron chelators. Free Radic. Biol. Med., 2003, 34, 1295-1305.
140. Lloyd, J. B.; Cable, H.; Rice-Evans, C. Evidence that desferrioxamine cannot enter cells by passive diffusion. Biochem. Pharmacol., 1991, 41, 1361-1363.
141. Cable, H.; Lloyd, J. B. Cellular uptake and release of two contrasting iron chelators. J. Pharm. Pharmacol., 1999, 51, 131-134.
142. Mak, I. T.; Weglicki, W. B. Characterization of iron-mediated peroxidative injury in isolated hepatic lysosomes. J. Clin. Invest., 1985, 75, 58-63.
143. Link, G.; Pinson, A.; Hershko, C. Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility. J. Lab. Clin. Med., 1993, 121, 127-134.
144. Persson, H. L.; Vainikka, L. K. Increased Lysosomal Membrane Permeabilization in Oxidant-exposed Macrophages of Human Fibrotic Lungs. J. Cell Death, 2013, 69-74.
145. Dolma, S.; Lessnick, S. L.; Hahn, W. C.; Stockwell, B. R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell, 2003, 3, 285-296.
146. Huang, H. S.; Chen, C. J.; Suzuki, H.; Yamamoto, S.; Chang, W. C. Inhibitory effect of phospholipid hydroperoxide glutathione peroxidase on the activity of lipoxygenases and cyclooxygenases. Prostaglandins Other Lipid Mediat., 1999, 58, 65-75.
147. Conrad, M. Transgenic mouse models for the vital selenoenzymes cytosolic thioredoxin reductase, mitochondrial thioredoxin reductase and glutathione peroxidase 4. Biochim. Biophys. Acta-Gen. Subj., 2009, 1790, 1575-1585.
148. Seiler, A.; Schneider, M.; Förster, H.; Roth, S.; Wirth, E. K.; Culmsee, C.; Plesnila, N.; Kremmer, E.; Rådmark, O.; Wurst, W.; Bornkamm, G. W.; Schweizer, U.; Conrad, M. Glutathione Peroxidase 4 Senses and Translates Oxidative Stress into 12/15-Lipoxygenase Dependent-And AIF-Mediated Cell Death. Cell Metab., 2008, 8, 237-248.
149. Yoo, S. E.; Chen, L.; Na, R.; Liu, Y.; Rios, C.; Van Remmen, H.; Richardson, A.; Ran, Q. Gpx4 ablation in adult mice results in a lethal phenotype accompanied by neuronal loss in brain. Free Radic. Biol. Med., 2012, 52, 1820-1827.
150. Yoo, S. E.; Chen, L.; Na, R.; Liu, Y.; Rios, C.; Van Remmen, H.; Richardson, A.; Ran, Q. Gpx4 ablation in adult mice results in a lethal phenotype accompanied by neuronal loss in brain. Free Radic. Biol. Med., 2012, 52, 1820-1827.
151. Ueta, T.; Inoue, T.; Furukawa, T.; Tamaki, Y.; Nakagawa, Y.; Imai, H.; Yanagi, Y. Glutathione peroxidase 4 is required for maturation of photoreceptor cells. J. Biol. Chem., 2012, 287, 7675-7682.
152. Wortmann, M.; Schneider, M.; Pircher, J.; Hellfritsch, J.; Aichler, M.; Vegi, N.; Kölle, P.; Kuhlencordt, P.; Walch, A.; Pohl, U.; Bornkamm, G. W.; Conrad, M.; Beck, H. Combined deficiency in glutathione peroxidase 4 and vitamin e causes multiorgan thrombus formation and early death in mice. Circ. Res., 2013, 113, 408-417.
153. Pedro, J.; Angeli, F.; Schneider, M.; Proneth, B.; Tyurina, Y. Y.; Tyurin, V. a; Hammond, V. J.; Herbach, N.; Aichler, M.; Walch, A.; Eggenhofer, E.; Basavarajappa, D.; Rådmark, O.; Kobayashi, S.; Seibt, T.; Beck, H.; Neff, F.; Esposito, I.; Wanke, R.; Förster, H.; Yefremova, O.; Heinrichmeyer, M.; Bornkamm, G. W.; Geissler, E. K.; Thomas, S. B.; Stockwell, B. R.; Donnell, V. B. O.; Kagan, V. E.; Schick, J. a; Conrad, M. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol., 2014, 16, 1180-1191.
154. Jiang, L.; Kon, N.; Li, T.; Wang, S.; Su, T.; Hibshoosh, H.; Baer, R.; Gu, W. Ferroptosis as a p53-mediated activity during tumour suppression. Nature, 2015.
155. Yabuki, Y.; Fukunaga, K. Oral administration of glutathione improves memory deficits following transient brain ischemia by reducing brain oxidative stress. Neuroscience, 2013, 250, 394-407.
156. Wendel, A.; Cikryt, P. The level and half-life of glutathione in human plasma. FEBS Lett., 1980, 120, 209-211.
157. Martínez Banaclocha, M.; Martínez, N. N-Acetylcysteine elicited increase in cytochrome c oxidase activity in mice synaptic mitochondria. Brain Res., 1999, 842, 249-251.
158. Farr, S. A.; Poon, H. F.; Dogrukol-Ak, D.; Drake, J.; Banks, W. A.; Eyerman, E.; Butterfield, D. A.; Morley, J. E. The antioxidants α-lipoic acid and N-Acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J. Neurochem., 2003, 84, 1173-1183.
159. McLellan, L. I.; Lewis, A. D.; Hall, D. J.; Ansell, J. D.; Wolf, C. R. Uptake and distribution of N-Acetylcysteine in mice: tissue-specific effects on glutathione concentrations. Carcinogenesis, 1995, 16, 2099-2106.
160. Kumar, T. R.; Wiseman, A. L.; Kala, G.; Kala, S. V; Matzuk, M. M.; Lieberman, M. W. Reproductive defects in γ-glutamyl transpeptidase-deficient mice. Endocrinology, 2000, 141, 4270-4277.
161. Mandal, P. K.; Seiler, A.; Perisic, T.; Kölle, P.; Canak, A. B.; Förster, H.; Weiss, N.; Kremmer, E.; Lieberman, M. W.; Bannai, S.; Kuhlencordt, P.; Sato, H.; Bornkamm, G. W.; Conrad, M. System xc-And thioredoxin reductase 1 cooperatively rescue glutathione deficiency. J. Biol. Chem., 2010, 285, 22244-22253.
162. Chen, Y.; Yang, Y.; Miller, M. L.; Shen, D.; Shertzer, H. G.; Stringer, K. F.; Wang, B.; Schneider, S. N.; Nebert, D. W.; Dalton, T. P. Hepatocyte-specific Gclc deletion leads to rapid onset of steatosis with mitochondrial injury and liver failure. Hepatology, 2007, 45, 1118-1128.
163. Iuchi, Y.; Okada, F.; Onuma, K.; Onoda, T.; Asao, H.; Kobayashi, M.; Fujii, J. Elevated oxidative stress in erythrocytes due to a SOD1 deficiency causes anaemia and triggers autoantibody production. Biochem. J., 2007, 402, 219-227.
164. Mahmoudi, G.A.; Astaraki, P.; Mohtashami, A. Z.; Ahadi, M. Nacetylcysteine overdose after acetaminophen poisoning. Int. Med. Case Rep. J., 2015, 65-69.
165. Botta, D.; White, C. C.; Vliet-Gregg, P.; Mohar, I.; Shi, S.; McGrath, M. B.; McConnachie, L. A.; Kavanagh, T. J. Modulating GSH synthesis using glutamate cysteine ligase transgenic and genetargeted mice. Drug Metab. Rev., 2008, 40, 465-477.
166. Mcconnachie, L. A.; Mohar, I.; Hudson, F. N.; Ware, C. B.; Ladiges, W. C.; Fernandez, C.; Chatterton-kirchmeier, S.; White, C. C.; Pierce, R. H.; Kavanagh, T. J. Glutamate cysteine ligase modifier subunit deficiency and gender as determinants of acetaminophen-Induced hepatotoxicity in mice. Toxicol. Sci., 2007, 99, 628-636.
167. Morris, D.; Guerra, C.; Donohue, C.; Oh, H.; Khurasany, M.; Venketaraman, V. Unveiling the mechanisms for decreased glutathione in individuals with HIV infection. Clin. Dev. Immunol., 2012, 2012.
168. Julius, M.; Lang, C. A.; Gleiberman, L.; Harburg, E.; DiFranceisco, W.; Schork, A. Glutathione and morbidity in a community-based sample of elderly. J. Clin. Epidemiol., 1994, 47, 1021-1026.
169. Nuttall, S. L.; Martin, U.; Sinclair, A. J.; Kendall, M. J. Glutathione: In sickness and in health. Lancet, 1998, 351, 645-646.
170. Alzoghaibi, M. A. Concepts of oxidative stress and antioxidant defense in Crohn's disease. World J. Gastroenterol., 2013, 19, 6540-7.
171. Williams, R. H.; Maggiore, J. A.; Reynolds, R. D.; Helgason, C. M. Novel approach for the determination of the redox status of homocysteine and other aminothiols in plasma from healthy subjects and patients with ischemic stroke. Clin. Chem., 2001, 47, 1031-1039.
172. Shimizu, H.; Kiyohara, Y.; Kato, I.; Kitazono, T.; Tanizaki, Y.; Kubo, M.; Ueno, H.; Ibayashi, S.; Fujishima, M.; Iida, M. Relationship between plasma glutathione levels and cardiovascular disease in a defined population: The Hisayama study. Stroke, 2004, 35, 2072-2077.
173. Kharb, S. Low blood glutathione levels in acute myocardial infarction. Indian J. Med. Sci., 2003, 57, 335-7.
174. Lee, T. D.; Sadda, M. R.; Mendler, M. H.; Bottiglieri, T.; Kanel, G.; Mato, J. M.; Lu, S. C. Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis. Alcohol. Clin. Exp. Res., 2004, 28, 173-181.
175. Videla, L. A.; Rodrigo, R.; Orellana, M.; Fernandez, V.; Tapia, G.; Quiñones, L.; Varela, N.; Contreras, J.; Lazarte, R.; Csendes, A.; Rojas, J.; Maluenda, F.; Burdiles, P.; Diaz, J. C.; Smok, G.; Thielemann, L.; Poniachik, J. Oxidative stress-related parameters in the liver of non-Alcoholic fatty liver disease patients. Clin. Sci. (Lond)., 2004, 106, 261-268.
176. Kalhan, S. C.; Guo, L.; Edmison, J.; Dasarathy, S.; McCullough, A. J.; Hanson, R. W.; Milburn, M. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism, 2011, 60, 404-413.
177. Lagman, M.; Ly, J.; Saing, T.; Kaur Singh, M.; Vera Tudela, E.; Morris, D.; Chi, P.-T.; Ochoa, C.; Sathananthan, A.; Venketaraman, V. Investigating the Causes for Decreased Levels of Glutathione in Individuals with Type II Diabetes. PLoS One, 2015, 10, e0118436.
178. Nwose, E. U.; Jelinek, H. F.; Richards, R. S.; Kerr, P. G. Changes in the erythrocyte glutathione concentration in the course of diabetes mellitus. Redox Rep., 2006, 11, 99-104.
179. Gamcsik, M.; Kasibhatla, M.; Teeter, S. Glutathione levels in human tumors. Biomarkers, 2013, 17, 671-691.